- Home
- CV vs URGN Comparison
CV vs URGN Comparison
Compare CV & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CV
- URGN
- Stock Information
- Founded
- CV 2005
- URGN 2004
- Country
- CV United States
- URGN United States
- Employees
- CV N/A
- URGN N/A
- Industry
- CV
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- CV
- URGN Health Care
- Exchange
- CV NYSE
- URGN Nasdaq
- Market Cap
- CV 194.2M
- URGN 181.2M
- IPO Year
- CV 2025
- URGN 2017
- Fundamental
- Price
- CV $4.54
- URGN $15.27
- Analyst Decision
- CV
- URGN Strong Buy
- Analyst Count
- CV 0
- URGN 8
- Target Price
- CV N/A
- URGN $29.00
- AVG Volume (30 Days)
- CV 1.0M
- URGN 1.6M
- Earning Date
- CV 01-01-0001
- URGN 08-12-2025
- Dividend Yield
- CV N/A
- URGN N/A
- EPS Growth
- CV N/A
- URGN N/A
- EPS
- CV N/A
- URGN N/A
- Revenue
- CV $12,044,000.00
- URGN $91,871,000.00
- Revenue This Year
- CV N/A
- URGN $39.80
- Revenue Next Year
- CV N/A
- URGN $108.94
- P/E Ratio
- CV N/A
- URGN N/A
- Revenue Growth
- CV 20.54
- URGN 8.98
- 52 Week Low
- CV $3.49
- URGN $3.42
- 52 Week High
- CV $5.72
- URGN $17.00
- Technical
- Relative Strength Index (RSI)
- CV N/A
- URGN 66.88
- Support Level
- CV N/A
- URGN $13.79
- Resistance Level
- CV N/A
- URGN $15.24
- Average True Range (ATR)
- CV 0.00
- URGN 0.81
- MACD
- CV 0.00
- URGN -0.05
- Stochastic Oscillator
- CV 0.00
- URGN 82.74
About CV CAPSOVISION INC
CapsoVision Inc is a commercial-stage medical technology enterprise, innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company's core technology platform is an orally ingestable capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. The Company's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D directed at the large intestines.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.